RAPT Therapeutics, Inc.

Report azionario NasdaqGM:RAPT

Capitalizzazione di mercato: US$1.8b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

RAPT Therapeutics Gestione

Criteri Gestione verificati 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEOn/a
Mandato del CEOno data
Proprietà del CEOn/a
Durata media del management3.2yrs
Durata media del Consiglio di amministrazione1.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

Seeking Alpha • Jan 20

RAPT Therapeutics: A Buy As GSK Acquisition Highlights Long-Acting IgE Candidate

Summary RAPT Therapeutics, Inc. is being acquired by GSK plc, aka GlaxoSmithKline, for $2.2 billion, driven by its promising anti-IgE antibody ozureprubart. Ozureprubart offers a potential best-in-class profile with extended half-life, enabling dosing every 8–12 weeks versus XOLAIR’s 2–4 weeks. The Phase 2b prestIgE trial is underway for IgE-mediated food allergy, leveraging strong proof-of-concept data in chronic spontaneous urticaria. I maintain a Buy rating on RAPT, citing pipeline progress, the acquisition that happened, and the broad applicability of ozureprubart to IgE-mediated disorders. Read the full article on Seeking Alpha
Articolo di analisi • Jul 16

We're Keeping An Eye On RAPT Therapeutics' (NASDAQ:RAPT) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Articolo di analisi • Mar 28

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Feb 16

Still Cautious Over RAPT Therapeutics' Fresh Start With RPT904

Summary RAPT Therapeutics pivoted from a failed inflammation asset (RPT193) to focus on RPT904 for food allergies. RPT904, an IgE-inhibiting mAb licensed from Jemincare, is in Phase 2 for food allergy, CSU, and asthma. The licensing deal includes a $35 million upfront fee plus milestones and royalties, with rights outside China, Hong Kong, and Macau. This gives RAPT a new “fresh start” with roughly $241.4 million in resources to fund its latest bet on RPT904 targeting FA. However, I’m still neutral on RAPT, as the recently issued shares could be a headwind. Also, the company’s bet on RPT904 remains speculative until Jemincare reports its Phase 2 data. Read the full article on Seeking Alpha
Articolo di analisi • Nov 10

Can RAPT Therapeutics (NASDAQ:RAPT) Afford To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jul 24

RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus

Summary Data from phase 2b study, using zelnecirnon for the treatment of patients with atopic dermatitis, is expected in Q3 of 2024; Potential for FDA clinical hold to be removed. The global atopic dermatitis market is expected to reach a valuation of $19.49 billion by the end of 2034. Preliminary ORR data established shows that tivumecirnon might ultimately be effective in treating CPI-naive NSCLC and CPI-experienced advanced HNSCC patients. The company had $141.6 million in cash as of March 31st of 2024; enough to fund its operations for at least the next 12 months. Read the full article on Seeking Alpha
Articolo di analisi • Jun 13

Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • May 20

RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity

Summary RAPT Therapeutics' lead candidate, zelnecirnon, is in phase 2 for atopic dermatitis and asthma with very promising ph1b results in atopic dermatitis and potential expansion in multiple indications. Liver failure in a single patient with a complex medical history resulted in a clinical hold by the FDA, leaving RAPT no choice but to unblind both ongoing ph2 studies. The probability that zelnecirnon caused the hepatic failure is low considering alternative explanations and no prior preclinical/clinical evidence of liver toxicity. If ph1b results are replicated, I expect the ph2 readout to be positive with available patients, despite premature halting of the trial. Subsequently, I expect the lifting of the FDA clinical hold. Read the full article on Seeking Alpha
Articolo di analisi • Feb 21

Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Articolo di analisi • Sep 12

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • May 10

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Feb 07

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Articolo di analisi • Oct 12

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Articolo di analisi • Jan 25

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Oct 15

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Articolo di analisi • Jun 08

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Articolo di analisi • Mar 15

Should You Take Comfort From Insider Transactions At RAPT Therapeutics, Inc. (NASDAQ:RAPT)?

It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...

AMMINISTRATORE DELEGATO

RAPT Therapeutics non ha un CEO, o non abbiamo dati su di loro.

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
William Ho
Strategic Consultant10.8yrsUS$2.31m0.0079%
$ 141.4k
Justin Huang
Presidentno dataNessun datoNessun dato
Steve Young
Vice President of Technologyno dataNessun datoNessun dato
Dirk Brockstedt
Chief Scientific Officer6.8yrsUS$1.48mNessun dato
Michael Listgarten
General Counsel3.2yrsNessun datoNessun dato
Paul Kassner
Senior Vice President of Biology6yrsNessun datoNessun dato
Jennifer Nicholson
Senior Vice President of Regulatory Affairs & Quality Assurance3.5yrsNessun datoNessun dato
Nipun Davar
Senior Vice President of Technical Operations2.1yrsNessun datoNessun dato
Lisa Moore
Senior Vice President of Business Development & Strategy1.1yrsNessun datoNessun dato
Kevin Ryan
VP, Treasurer & Directorno dataNessun datoNessun dato
3.2yrs
Durata media
57.5yo
Età media

Gestione esperta: Il team dirigenziale di RAPT è considerato esperto (durata media dell'incarico 3.2 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Justin Huang
Presidentno dataNessun datoNessun dato
Kevin Ryan
VP, Treasurer & Directorno dataNessun datoNessun dato
Hugh Sampson
Member of Scientific Advisory Board1.2yrsNessun datoNessun dato
Alexander Rudensky
Chairman of Scientific Advisory Boardno dataNessun datoNessun dato
Emma Guttman-Yassky
Member of Scientific Advisory Board6.7yrsNessun datoNessun dato
Robert Zamboni
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Lisa Beck
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Sharon Chinthrajah
Member of Scientific Advisory Board1.2yrsNessun datoNessun dato
1.2yrs
Durata media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di RAPT non è considerato esperto (durata media del mandato 1.2 anni), il che suggerisce un nuovo consiglio.

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/03/05 02:05
Prezzo dell'azione a fine giornata2026/03/02 00:00
Utili2025/09/30
Utili annuali2024/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

RAPT Therapeutics, Inc. è coperta da 7 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Gao Yi ChenBerenberg
Guyn KimBMO Capital Markets Equity Research
Zegbeh JallahCapital One Securities, Inc.